[HTML][HTML] GD2-targeting therapy: a comparative analysis of approaches and promising directions
J Philippova, J Shevchenko, S Sennikov - Frontiers in Immunology, 2024 - frontiersin.org
Disialoganglioside GD2 is a promising target for immunotherapy with expression primarily
restricted to neuroectodermal and epithelial tumor cells. Although its role in the maintenance …
restricted to neuroectodermal and epithelial tumor cells. Although its role in the maintenance …
[PDF][PDF] GD2-targeting therapy: a comparative analysis of approaches and promising directions
J Philippova, J Shevchenko, S Sennikov - 2024 - pdfs.semanticscholar.org
Tumor immunotherapy targeting tumor-associated antigen (TAA) using monoclonal
antibodies (mAbs) or immunocompetent cells can improve standard therapeutic methods …
antibodies (mAbs) or immunocompetent cells can improve standard therapeutic methods …
[HTML][HTML] GD2-targeting therapy: a comparative analysis of approaches and promising directions
J Philippova, J Shevchenko, S Sennikov - Frontiers in Immunology, 2024 - ncbi.nlm.nih.gov
Disialoganglioside GD2 is a promising target for immunotherapy with expression primarily
restricted to neuroectodermal and epithelial tumor cells. Although its role in the maintenance …
restricted to neuroectodermal and epithelial tumor cells. Although its role in the maintenance …
GD2-targeting therapy: a comparative analysis of approaches and promising directions
J Philippova, J Shevchenko… - Frontiers in …, 2024 - pubmed.ncbi.nlm.nih.gov
Disialoganglioside GD2 is a promising target for immunotherapy with expression primarily
restricted to neuroectodermal and epithelial tumor cells. Although its role in the maintenance …
restricted to neuroectodermal and epithelial tumor cells. Although its role in the maintenance …
GD2-targeting therapy: a comparative analysis of approaches and promising directions.
J Philippova, J Shevchenko, S Sennikov - Frontiers in Immunology, 2024 - europepmc.org
Disialoganglioside GD2 is a promising target for immunotherapy with expression primarily
restricted to neuroectodermal and epithelial tumor cells. Although its role in the maintenance …
restricted to neuroectodermal and epithelial tumor cells. Although its role in the maintenance …
GD2-targeting therapy: a comparative analysis of approaches and promising directions.
J Philippova, J Shevchenko, S Sennikov - Frontiers in Immunology, 2024 - europepmc.org
Disialoganglioside GD2 is a promising target for immunotherapy with expression primarily
restricted to neuroectodermal and epithelial tumor cells. Although its role in the maintenance …
restricted to neuroectodermal and epithelial tumor cells. Although its role in the maintenance …